The drug raised IGF-I levels by about 1.7 standard deviations — a big, normal-range boost that shows the treatment worked well without going overboard.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Randomized Controlled Trial

Human

2014 Jan

This study found that a drug called tesamorelin boosted a growth-related hormone (IGF-I) in obese people with low growth hormone, and this boost was big enough to be helpful for their body’s energy production — which matches the claim that the increase was meaningful and normal.

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Source Study

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Score: 61

DOI: 10.1210/jc.2013-3436

Similar Assertions

After a year of taking tesamorelin, obese people with low growth hormone had much higher levels of IGF-I than those who took a sugar pill — proving the drug works as intended.

86%

In people who took tesamorelin, the more their IGF-I levels went up, the better their muscles recovered after exercise — and this link was even stronger than in the whole group.

84%

Taking tesamorelin for a year makes the hormone IGF-I go up much more in obese people with low growth hormone compared to taking a sugar pill.

80%

Taking tesamorelin for a year makes IGF-I levels rise much more in obese people with low growth hormone than taking a dummy pill, with a clear difference between the two groups.

80%

Instead of giving growth hormone directly, this drug tricks the body into making its own in a natural rhythm, which might be safer for blood sugar.

78%